Oct 29, 2026 · 11 min
Drugmakers rally as tech earnings expose AI spending fault lines
Merck Reports; Big Tech Earnings; Marvell-Lumentum Latest
The episode shows how guidance, cloud growth, advertising concerns, and long-term investment plans are reshaping market reactions across industries.
- 1Eli Lilly and Merck gain as strong drug sales support higher forecasts and renewed confidence in growth.
- 2Caterpillar falls despite beating earnings, while Microsoft benefits from Azure strength and disciplined capital spending.
- 3Alphabet’s weaker advertising and search outlook contrasts with a broader discussion of AI, urban growth, and SpaceX’s demanding culture.
Don't miss
Microsoft’s gains and Alphabet’s weakness crystallize how differently investors are judging AI spending, cloud strength, and advertising resilience.
The brief
Eli Lilly and Merck rally after strong drug sales and raised forecasts, while Caterpillar’s more cautious growth outlook drags on its shares despite an earnings beat.
Microsoft gains on Azure strength and lower-than-expected capital expenditures, but Alphabet faces pressure over advertising and search performance amid AI disruption.
Nathan Hager and Dan Curtis frame the earnings reactions as a test of how investors are weighing growth, guidance, and the cost of competing in AI.
The episode then turns to SpaceX’s demanding hiring culture, where exceptional achievement and alignment with Elon Musk’s standards shape the candidate experience.
A closing discussion on smarter cities explores how AI, infrastructure innovation, and Dubai’s long-term planning can help rapidly growing urban systems keep pace.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.